Fidan S, Capkın E, Arıca DA, et al. - Researchers aimed at determining hepatitis B virus (HBV) screening rates in patients undergoing anti‐tumor necrosis factor (TNF)‐α therapy. In addition, they ascertained the frequency of HBV reactivation in patients with resolved hepatitis B virus infection (hepatitis B surface antigen [HBsAg] negative, hepatitis B core antibody [Anti‐HBc] positive). They performed retrospective analysis of data from 1,834 patients who underwent anti‐TNF‐α therapy. Observations revealed the overall HBV screening rate of 82.3% prior to initiation of anti‐TNF‐α therapy indicating relatively high hepatitis B virus screening rates before starting anti‐TNF‐α therapy. They indicated an increasing trend in HBV screening rates during the years analyzed. Patients with resolved HBV infection rarely had HBV reactivation because of anti‐TNF‐α use.